Redaelli et al. investigated the activity of imatinib, dasatinib, bosutinib, and nilotinib against a panel of 18 mutated forms of BCR/ABL1 associated with imatinib resistance in CML and ALL. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.